Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

Our Products
Overview
Partnering Search
Company Profiling
Partneringtools
Reports
Partnering Consulting
Comparison
 
Forums
Visit our forums
 
Jobs
Visit our job site
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire New!
 
Contact us
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing Ltd
is a division of
UTEK Corporation
Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 1..10 of 37 - per page Next page
Order by
Novel agent for the detection of and assessment of the severity of myocardial ischemia with significantly reduced side effects to current marketed products More
A renowned cardiologist and Robarts' Scientist has identified a strong correlation between a polymorphism of a relatively new apolipoprotein gene and severity of hypertiglyceridemia manifestation. More
This invention relates to a computer-controlled physiological flow simulator for use in the study of vascular hemodynamics and the calibration of clinical imaging systems used to measure blood flow More
A novel non-invasive method for using carbon-13 magnetization transfer effects to determine and evaluate in vivo aspartate transaminase (AST) activity and levels in an organ, as a biomarker of disease and certain neurological disorders. More
"A comprehensive set of samples in various diseases. The resource consists of DNA samples from 16 diseases (Type I diabetes, Type II diabetes, Asthma, Colorectal Cancer, Breast Cancer, Prostate Cancer, Alzheimer's disease, Parkinson's disease... More
his invention concerns a system and method of obtaining four-dimensional (4-D) ultrasound images of moving tissue such as the human heart or lungs, where time is the fourth dimension. More
Use of depth filters to remove prion infectivity from plasma - derived therapeutic products and/or other biologics. Depth Filtration is a chemically inactive process and therefore does not introduce potentially toxic bi-products or alter components. More
Western inventors have identified a group of 12 differentially expressed proteins in Preeclampsia (PE) patients using a state-of-art proteomics based approach. More
Blood samples are fixed immediately from the patient and stored for up to 6 days at room temperature before platelet activation is assessed via P-selectin measurements. These measurements are of interest in order to diagnose cardiovascular disease More
Proprietary manufacturing process for a liquid IVIgG product - in great demand world-wide as one of the principal therapeutics obtained from blood plasma. Process delivers a low IgA content, which increases renal tolerability. More
Displaying 1..10 of 37 - per page Next page
Order by
Partnering consultation free of charge
Need competitive intelligence information
Cell & Gene Therapy Forum 2009
Industry news: Pharmalicensing provides comprehensive industry coverage.

© Copyright 1995-2008 Pharmalicensing Ltd, is a division of UTEK Corporation All rights reserved. Terms and Conditions | Site map | Contact us